Table 4.
Clinicopathologic characteristics of the RA patients and HC donors from validation cohort.
| Discovery cohort | RA (n=20) | HC (n=20) |
|---|---|---|
| Age, (mean ± SD) | 37 ± 9 | 33 ± 9 |
| Sex, Female (%) | 19 (95) | 19 (95) |
| Disease duration years, (mean ± SD) | 6.1 (0.25-20) | |
| SJC, (mean (range)) | 4 (0-20) | |
| TJC, (mean (range)) | 5 (0-20) | |
| ESR, (mm/hour, (mean ± SD)) | 32.8 ± 27.0 | |
| CRP, (mg/L, (mean ± SD)) | 11.0 ± 15.9 | |
| RF positive (%) | 11 (55) | |
| CCP positive (%) | 12 (60) | |
| DAS28 score, (mean ± SD) | 3.9 ± 1.4 | |
| ANA positive (%) | 6 (30) | |
| Low C3 (%) | 4 (20) | |
| Low C4 (%) | 6 (30) | |
| IGA, (g/L, (mean ± SD)) | 2.5 ± 1.0 | |
| IGG, (g/L, (mean ± SD)) | 16.3 ± 8.2 | |
| IGM, (g/L, (mean ± SD)) | 1.4 ± 0.6 | |
| Current drug use | ||
| Oral glucocorticoid treatment (%) | 9 (45) | |
| DMARD (%) | 19 (95) | |
| Oral anticoagulant (%) | 0 | |
| Aspirin (%) | 0 | |
| Biologics (%) | 0 | |
| Tripterygium glycosides (%) | 1 (5) | |
SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score (28-joint count); ANA, anti-nuclear antibody; C3, complement 3; C4, complement 4; IGA, immunoglobulin A; IGG, immunoglobulin G; IGM, immunoglobulin M; DMARD, disease modifying antirheumatic drug.